Leadership Team

A highly experienced team with a strong track record of performance

The ImmVirX team comprises key directors and the executive and scientific staff from Viralytics, a clinical-stage oncolytic virus company acquired in June 2018 by Merck and Co. Inc. for A$502 million.

Leadership

Board

Management Team

In the News

View our recent news stories

Discover the latest news articles featuring ImmVirX, including research innovations, stories about our people and reports from the latest events.

View All Stories

Join Our Mailing List

Our mission is to improve outcomes for patients with cancers in which immunotherapy treatments have limited effect

About Us
Our Technology
Immvirx logo
A clinical stage company developing novel oncolytic viruses to create powerful new cancer immunotherapy combinations
Twitter Linkedin
Company
© 2020 ImmVirX Pty Ltd • Site by Alex Shafren & Noise